|
|
Steven Grant
J Clin Invest. 2008;
118(10):3513
doi:10.1172/JCI36898E1
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(12)
| Title and authors |
Publication |
Year |
miR-520c and miR-373 upregulate MMP9 expression by targeting mTOR and SIRT1, and activate the Ras/Raf/MEK/Erk signaling pathway and NF-κB factor in human fibrosarcoma cells
Michael J. Wilson, Ping Liu
|
J. Cell. Physiol.
|
2012 |
Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein Kinase (MAPK) and Phosphatidylinositol-3-kinase (PI3K)/AKT pathways
Jun-ichi Hanai, Nathaniel Doro, Atsuo T. Sasaki, Susumu Kobayashi, Lewis C. Cantley, Pankaj Seth, Vikas P. Sukhatme
|
J. Cell. Physiol.
|
2012 |
ERK2 is essential for the growth of human epithelioid malignant mesotheliomas
Arti Shukla, Jedd M. Hillegass, Maximilian B. MacPherson, Stacie L. Beuschel, Pamela M. Vacek, Kelly J. Butnor, Harvey I. Pass, Michele Carbone, Joseph R. Testa, Nicholas H. Heintz, Brooke T. Mossman
|
Int. J. Cancer
|
2011 |
RSK in tumorigenesis: connections to steroid signaling.
T S Karin Eisinger-Mathason, Josefa Andrade, Deborah A Lannigan
|
Steroids
|
2010 |
Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244
Sylwia Ammoun, Natalia Ristic, Cordula Matthies, David A. Hilton, C. Oliver Hanemann
|
Neurobiology of Disease
|
2010 |
Compensatory activation of Akt in response to mTOR and Raf inhibitors – A rationale for dual-targeted therapy approaches in neuroendocrine tumor disease
Kathrin Zitzmann, Janina von Rüden, Stephan Brand, Burkhard Göke, Jennifer Lichtl, Gerald Spöttl, Christoph J. Auernhammer
|
Cancer Letters
|
2010 |
Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy.
Paul Dent, David T Curiel, Paul B Fisher, Steven Grant
|
Drug Resist. Updat.
|
2009 |
New agents for AML and MDS.
Steven Grant
|
Best Pract Res Clin Haematol
|
2009 |
Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells.
Peter W Schlosshauer, Wei Li, Kai-Ti Lin, Joseph L-K Chan, Lu-Hai Wang
|
Gynecologic Oncology
|
2009 |
Potent growth suppressive activity of curcumin in human breast cancer cells: Modulation of Wnt/β-catenin signaling
Chandra P. Prasad, Gayatri Rath, Sandeep Mathur, Dinesh Bhatnagar, Ranju Ralhan
|
Chemico-Biological Interactions
|
2009 |
|